FourThought Financial Partners LLC Lowers Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

FourThought Financial Partners LLC lowered its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 706 shares of the biopharmaceutical company’s stock after selling 12 shares during the period. FourThought Financial Partners LLC’s holdings in Regeneron Pharmaceuticals were worth $620,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at about $26,000. Fortitude Family Office LLC purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the last quarter. Criterion Capital Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $37,000. Finally, Sutton Wealth Advisors Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 13 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently weighed in on REGN. TD Cowen lifted their target price on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Barclays boosted their price objective on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an “overweight” rating in a report on Tuesday, January 23rd. Truist Financial restated a “buy” rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 30th. Finally, UBS Group raised their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $977.77.

Insider Activity

In related news, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at approximately $46,203,239.82. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now directly owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. In the last three months, insiders sold 10,095 shares of company stock valued at $9,664,476. Insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.1 %

REGN stock traded up $19.39 during midday trading on Friday, reaching $957.00. 547,373 shares of the company were exchanged, compared to its average volume of 509,442. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 6.40. The stock’s 50-day simple moving average is $943.75 and its 200 day simple moving average is $897.24. The company has a market cap of $105.04 billion, a price-to-earnings ratio of 28.27, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17. Regeneron Pharmaceuticals, Inc. has a 1-year low of $684.80 and a 1-year high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. The firm had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. Regeneron Pharmaceuticals’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company earned $10.96 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.86 earnings per share for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.